



11-24-03

1639

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/057,178	
	Filing Date	January 24, 2002	
	First Named Inventor	Kit S. Lam	
	Art Unit	1639	
	Examiner Name	Jon D. Epperson	
Total Number of Pages in This Submission	7	Attorney Docket Number	8141/9886

RECEIVED  
DEC 01 2003  
TECH CENTER 1639/2900

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	1. Copy of Notice to Comply
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	2. Response to Notice to Comply
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	3. Return card
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Audrey A. Millemann, Reg. No. 44,942 Weintraub Genshlea Chediak Sproul
Signature	<i>Audrey A. Millemann</i>
Date	November 21, 2003

CERTIFICATE OF TRANSMISSION/MAILING (Express Mail No. EL93952976US)			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as Express Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Mail Stop Art Unit 1639			
Typed or printed name	Audrey A. Millemann		
Signature	<i>Audrey A. Millemann</i>	Date	Nov. 21, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**RECEIVED**

DEC 01 2003

TECH CENTER 1600/2900

Applicants: Kit S. Lam and Alan L. Lehman )  
)  
Serial No.: 10/057,178 )  
)  
Filed: January 24, 2002 )  
)  
For: Method for Determining )  
Differences in Molecular )  
Interactions and for Screening A )  
Combinatorial Library )  
\_\_\_\_\_ )

Art Unit: 1639  
Examiner: Jon D. Epperson

November 21, 2003  
Sacramento, California 95814

Mail Stop Art Unit 1639  
Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RESPONSE TO NOTICE TO COMPLY: SEQUENCE RULES

This paper is in response to the Notice to Comply: Sequence Rules (Bonafide) mailed by the Examiner on October 29, 2003.

The Examiner objected to the application on the grounds that it contains amino acid sequences within the meaning of 37 C.F.R. §1.821(a)(2) and does not comply with the requirements of 37 C.F.R. §§1.821-1.825. The Examiner referred to amino acid sequences disclosed on pages 32 and 33 of the specification, and requested that applicants check the entire specification for compliance.

Serial No.: 10/057,178  
Art Unit: 1639  
Attorney File No. 8141/9886

Applicants respectfully point out that 37 C.F.R. §1.821(a)(2) exempts amino acid sequences containing D-amino acids from the requirements of §§1.821-1.825, including submission of a "Sequence Listing." Subsection (a)(2) of §1.821 states:

"Those amino acid sequences containing D-amino acids are not intended to be embraced by this definition."

Subsection (b) of §1.821 states:

"Patent applications which contain disclosures of nucleotide and/or amino acid sequences, in accordance with the definition in paragraph (a) of this section, shall, with regard to the manner in which the nucleotide and/or amino acid sequences are presented and described, conform exclusively to the requirements of §§ 1.821 through 1.825."

Thus, amino acid sequences containing D-amino acids do not fall within the requirements of §§1.821 through 1.825. (See also *Manual of Patent Examining Procedure*, §§ 2421.02, 2422, and 2422.01.)

The only amino acid sequences disclosed in applicants' patent application are set forth on pages 32 and 33 of the specification, in the example of the method, which is described on pages 26-33. These were peptide ligands identified using the method of the invention. All of the peptide ligands disclosed contain the D-amino acid D-cysteine, as demonstrated by the fact that the combinatorial library from which the ligands were obtained was a peptide library having the general structure of cXXXXXXc, where "c" is D-cysteine. (Specification, 20:5-6; see also specification,


Serial No.: 10/057,178  
Art Unit: 1639  
Attorney File No. 8141/9886

17:17-19). Because all of the ligands disclosed contain a D-amino acid, §§1.821-1.825 do not apply and no correction to the specification is necessary.

Respectfully submitted,

KIT S. LAM and ALAN L. LEHMAN


Date: November 21, 2003

By:   
Audrey A. Millemann (Reg. No. 44,942)  
Attorney for Applicants  
Weintraub Genshlea Chediak Sproul  
Law Corporation  
400 Capitol Mall, Eleventh Floor  
Sacramento, California 95814  
916/558-6033



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov



APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/057,178	01/24/2002	Kit S. Lam	8141/9886	5311

Audrey A. Millemann  
Weintraub Genshlea Chediak Sproul Law Corporation  
11th Floor  
400 Capitol Mall  
Sacramento, CA 95814

EXAMINER

EPPERSON, JON D

ART UNIT	PAPER NUMBER
----------	--------------

1639

DATE MAILED: 10/29/2003

5

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED  
DEC 01 2003  
TECH CENTER 1600/2900



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, DC 20231  
www.uspto.gov*Applicant Copy*

APPLICATION NO/CONTROL NO. 10/057,178	FILING DATE 1/24/2002	FIRST NAMED INVENTOR /PATENT IN REEXAMINATION Lam et al	ATTORNEY DOCKET NO. 8141/9886
--	--------------------------	--	----------------------------------



EXAMINER Jon D. Epperson
-----------------------------

ART UNIT 1639	PAPER 5
------------------	------------

RECEIVED

DATE MAILED: DEC 01 2003

TECH CENTER 1600/2900

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

## Notice To Comply: Sequence Rules (Bonafide)

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the following reason(s): For example, see bottom of 32 and top of page 33 wherein multiple amino acid sequences are disclosed (e.g., HTLHQ). Please also re-check the entire specification for compliance. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

**APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825.** Failure to comply with these requirements will result in **ABANDONMENT** of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

1. Electronically submitted through EFS-Bio  
(<http://www.uspto.gov/ebs/efs/downloads/documents.htm>), EFS Submission User Manual - ePAVE)


2. Mailed to:

U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

Any inquiry concerning this communication should be directed to Jon D. Epperson whose telephone number is (703) 308-2423. The Examiner can normally be reached on Monday through Friday from 9 am to 6 pm. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Andrew Wang, can be reached at (703) 306-3217. The fax number for this group is (703) 305-3014. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the group receptionist whose telephone number is (703) 308-0196.

Jon D. Epperson  
AU 1639

BENNETT CELSA  
PRIMARY EXAMINER



<b>Notice to Comply</b>	<b>Application N</b> 10/057,178	<b>Applicant(s)</b> Lam et al	
	<b>Examiner</b> Jon D. Epperson	<b>Art Unit</b> 1639	<b>Paper No</b> 5

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: For example, see bottom of 32 and top of page 33 e.g., HTLHQ. Re-check entire spec.

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 or (703) 308-2923

For CRF Submission Help, call (703) 308-4212

Patent Software Program Support

Technical Assistance.....703-287-0200

To Purchase Patent Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**

**RECEIVED**

DEC 01 2003

TECH CENTER 1600/2800